(PFE) is running a late-stage trial to test a new pneumococcal vaccine in healthy infants. The official title describes a Phase 3, randomized, double-blind study that compares a multivalent ...
Pfizer Inc. PFE on Wednesday reported positive Phase 2 data for its investigational 25-valent pneumococcal conjugate vaccine ...
Pfizer Inc. (NYSE:PFE) is one of the best medical stocks to invest in according to billionaires. Pfizer Inc. (NYSE:PFE) ...
(NEXSTAR) – The Pfizer/BioNTech vaccine may be less effective against the South African strain of the coronavirus than other variations circulating in the population, a new study out of Israel has ...
May 20 (Reuters) - Pfizer said on Wednesday its experimental pneumococcal vaccine showed significantly stronger immune ...
Pfizer said it will seek regulatory approval for a Lyme disease vaccine candidate despite failing a late-stage trial. Pfizer said not enough people contracted Lyme disease to be confident in the ...
Shares of German drug maker BioNTech SE rallied 24 per cent, while US-based Pfizer Inc. stock jumped over 14 per cent in pre-market trading on Monday after their COVID-19 vaccine candidate achieved ...
Vaccines that protect against severe illness, death and lingering long Covid symptoms from a coronavirus infection were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results